Lupin has received Establishment Inspection Report (EIR) from USFDA for its Pithampur (Unit-3) facility in Indore in the state of Madhya Pradesh. The inspection was conducted between October 8, 2018 to October 18, 2018. Lupin’s Pithampur Unit-3 is involved in the manufacture of Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Topical Formulations for the regulated markets.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.